Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations
Galderma will present data on Nemluvio® (nemolizumab) in atopic dermatitis and prurigo nodularis at the Revolutionizing Atopic Dermatitis (RAD) Conference, taking place from June 6-7, 2025.
First author | Abstract title | Presentation type |
J. Silverberg | Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis | Late breaking oral presentation Saturday, June 7, 4:00 – 5:30 PM CDT |
J. Silverberg | Nemolizumab was associated with rapid and significant improvements in itch and sleep in patients with moderate-to-severe atopic dermatitis: Results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2) | E-poster |
G. Yosipovitch | Nemolizumab long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis | E-poster |
P. Lio | Nemolizumab is associated with a low incidence of injection-site reactions in the treatment of atopic dermatitis and prurigo nodularis | E-poster |